Cilmi-baarista cusub ee Cleveland Clinic waxay muujineysaa markii ugu horreysay in FDA-ansixisay ibrutinib (ibrutinib) ee lymphoma iyo leukemia ay sidoo kale gacan ka geysan karto daaweynta burooyinka ugu caansan uguna daran ee maskaxda, waxaana laga yaabaa in maalin uun loo isticmaalo bukaanada qaba glioblastoma Iyo in la wanaajiyo heerarka badbaadada.
Sida laga soo xigtay warbixinta Ururka Maskaxda Maskaxda ee Mareykanka, heerka badbaadada glioblastoma waa mid aad u hooseeya, iyo badbaadada dhexdhexaadka ah ee bukaannada qaata daaweynta caadiga ah waa in ka yar 15 bilood. Cudurka 'Glioblastoma' waa kan ugu daran ee dila maskaxda wuxuuna aad ugu adkeystaa daaweynta hadda socota. Waxaa jirta baahi degdeg ah in bukaannadan loo siiyo daaweyn cusub sida ugu dhakhsaha badan ee suurtogalka ah.
In an earlier study, Bao and colleagues found that glioma stem cells contained high levels of a protein called BMX (bone marrow and X-linked non-receptor tyrosine kinase). BMX activates a protein called STAT3 (signal transduction and transcription activator 3), which is responsible for the invasive and tumorigenic properties of glioma stem cells. In this new study, the researchers found that ibrutinib works by inhibiting two proteins.
A research team led by Dr. Shideng Bao of the Cleveland Clinic Lerner Institute found that ibrutinib slowed the growth of brain burooyinka in a preclinical model and prolonged survival by more than 10 times that of existing standard chemotherapy drugs. Studies have found that ibrutinib works by inhibiting glioma stem cells, an aggressive brain cancer cell that tends to resist treatment and spread. In addition, combining ibrutinib with radiation therapy can prevent glioblastoma cells from developing drug resistance. Combination therapy is more effective than radiotherapy or ibrutinib alone in overcoming drug resistance and extending lifespan. Follow-up clinical trials are being carried out intensively, and we look forward to receiving FDA approval as soon as possible.
https://medicalxpress.com/news/2018-05-leukemia-lymphoma-drug-benefit-glioblastoma.html
